BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...
NEW ORLEANS, Feb. 20, 2019 /PRNewswire/ -- RightEye LLC, an award-winning health technology company that uses eye tracking to revolutionize patient care and improve vision performance, today announced ...
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to ...
VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in best-corrected visual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results